UH HYUN KIM | Bio Chemistry | Best Paper Award

Best Paper Award

UH HYUN KIM
Affiliation Wonkwang University
Country South Korea
Scopus ID 7102248950
ORCID 0000-0003-3304-7190
Documents 117
Citations 4,627
h-index 40
Subject Area Biochemistry
Event Best Paper Awards

UH HYUN KIM

UH HYUN KIM of Wonkwang University, South Korea is recognized with the Best Paper Award for research excellence in the field of Biochemistry [1]. The recognized research, titled “The Na+/K+-ATPase β1 Subunit is a Kidney ADP-Ribosyl Cyclase,” investigates the biochemical function of the Na+/K+-ATPase β1 subunit and its relationship with ADP-ribosyl cyclase activity in the kidney.

Abstract

This article recognizes UH HYUN KIM with the Best Paper Award for research excellence in Biochemistry [1]. The recognized research, titled “The Na+/K+-ATPase β1 Subunit is a Kidney ADP-Ribosyl Cyclase,” focuses on the functional characteristics of the Na+/K+-ATPase β1 subunit in kidney biology. The study highlights a biochemical relationship between this subunit and ADP-ribosyl cyclase activity, contributing to the broader understanding of membrane-associated proteins and biochemical signaling mechanisms.

Keywords

Best Paper Award, UH HYUN KIM, Biochemistry, Na+/K+-ATPase, β1 Subunit, Kidney, ADP-Ribosyl Cyclase, Kidney Biochemistry, Membrane Proteins, Enzyme Activity [1].

Introduction

The awarded research, “The Na+/K+-ATPase β1 Subunit is a Kidney ADP-Ribosyl Cyclase,” addresses an important biochemical question concerning the functional role of the Na+/K+-ATPase β1 subunit. The Na+/K+-ATPase system is associated with cellular ion regulation, while ADP-ribosyl cyclase activity is relevant to biochemical signaling processes. The research connects these concepts by examining the β1 subunit in the context of kidney-associated ADP-ribosyl cyclase activity [2].

Research Profile

UH HYUN KIM is affiliated with Wonkwang University, South Korea and is associated with the subject area of Biochemistry. According to the provided academic information, the researcher has 117 documents, 4,627 citations, and an h-index of 40. The Scopus author identifier supplied for the researcher is 7102248950 [3].

Research Contributions

The recognized publication contributes to Biochemistry by examining the functional identity of the Na+/K+-ATPase β1 subunit as a kidney ADP-ribosyl cyclase. By connecting a membrane-associated protein subunit with enzymatic activity, the research provides a basis for considering additional biochemical functions of the β1 subunit beyond its established structural association with Na+/K+-ATPase [2].

Research Impact

The provided academic profile records 117 documents, 4,627 citations, and an h-index of 40 for UH HYUN KIM [3]. These bibliometric indicators demonstrate an established scholarly publication record and substantial citation activity.

Award Suitability

The Best Paper Award recognizes outstanding research based on factors including originality, significance, research quality, and the contribution and impact of published work [1]. UH HYUN KIM’s recognized research aligns with these objectives through its investigation of the Na+/K+-ATPase β1 subunit and its association with kidney ADP-ribosyl cyclase activity.

Conclusion

UH HYUN KIM has an established research profile in Biochemistry, with the provided academic information recording 117 documents, 4,627 citations, and an h-index of 40 [3]. The recognized publication, “The Na+/K+-ATPase β1 Subunit is a Kidney ADP-Ribosyl Cyclase,” examines an important biochemical relationship involving the Na+/K+-ATPase β1 subunit and kidney ADP-ribosyl cyclase activity [2].

The combination of a focused biochemical research contribution and an established scholarly record supports the recognition of UH HYUN KIM in connection with the Best Paper Award [1].

External Links

References

  1. Best Paper Awards.
    International Research Excellence and Best Paper Awards. Best Paper Awards Website.
    https://bestpaperawards.com/
  2. UH HYUN KIM – Scopus Author Profile.
    Scopus Author ID: 7102248950.
    View Scopus Profile
  3. UH HYUN KIM – ORCID Profile.
    ORCID: 0000-0003-3304-7190.
    View ORCID Profile

Hemantha Mani Kumar Chakravarthi Chanda | Biochemistry | Young Scientist Award

Young Scientist Award

Hemantha Mani Kumar Chakravarthi Chanda
Vignan’s Foundation for Science, Technology & Research (Deemed to be University), India

Hemantha Mani Kumar Chakravarthi Chanda
Affiliation Vignan’s Foundation for Science, Technology & Research (Deemed to be University)
Country India
Scopus ID 60154587000
Documents 4
Citations 4
h-index 1
Subject Area Biochemistry
Event International Research Excellence and Best Paper Awards
ORCID 0009-0008-3418-3374

Hemantha Mani Kumar Chakravarthi Chanda is a researcher affiliated with Vignan’s Foundation for Science, Technology & Research (Deemed to be University), India, whose scholarly profile is associated with biochemistry. Available bibliographic information records four documents, four citations, and an h-index of one, providing an emerging profile for consideration within an academic recognition context.[1]

Abstract

Hemantha Mani Kumar Chakravarthi Chanda is an emerging biochemistry researcher affiliated with Vignan’s Foundation for Science, Technology & Research (Deemed to be University), India. The available scholarly record identifies four research documents and four citations, with an h-index of one, indicating an early stage of academic development.[1] His research profile is situated within biochemistry, a discipline encompassing molecular processes, biomolecules, cellular mechanisms, and biochemical interactions. The documented publication activity provides an initial basis for assessing research engagement, scholarly communication, and developing academic contribution. His ORCID record provides a persistent researcher identifier that can support accurate attribution of scholarly outputs.[2] The Young Scientist Award context recognizes emerging researchers whose developing work demonstrates academic promise, research participation, and potential for continued contribution to scientific knowledge. The available metrics should therefore be interpreted as indicators of an early-career research profile rather than as a complete assessment of scientific quality or long-term impact.

Keywords

Biochemistry, young scientist, scientific research, molecular biology, biochemical research, academic publications, research impact, scholarly communication, Vignan’s Foundation for Science, Technology & Research, Scopus, ORCID, scientific recognition.

Introduction

Biochemistry examines the chemical processes underlying living systems and connects molecular science with biological function. Researchers in this field contribute through experimentation, analysis, publication, and interdisciplinary collaboration. Chanda’s recorded affiliation and bibliographic profile place his emerging scholarly activity within this broader scientific framework and provide a basis for academic recognition.[1]

Research Profile

The available Scopus information lists four documents, four citations, and an h-index of one for Hemantha Mani Kumar Chakravarthi Chanda. These indicators describe a developing publication and citation record and should be considered alongside publication quality, research originality, methodological rigor, collaboration, and relevance to biochemistry.[1]

Research Contributions

Chanda’s contribution can be considered within the context of biochemistry and its interdisciplinary scientific applications. His documented research outputs demonstrate participation in scholarly publication, while the existing citation record indicates that some published work has entered the academic literature. Further assessment would require detailed examination of individual studies and methodologies.[1]

Publications

The indexed research profile currently records four documents associated with Scopus Author ID 60154587000. These publications form the documented scholarly output available for this recognition profile. Individual publication titles, journals, publication years, and DOI identifiers were not supplied in the source information and therefore are not inferred here.[1]

Research Impact

The recorded four citations indicate that the research outputs have received measurable scholarly attention within indexed literature. At an early career stage, citation counts may naturally remain limited, so research impact is better considered together with publication relevance, scientific contribution, reproducibility, collaboration, and future research development.[1]

Award Suitability

The profile may be considered in an emerging-researcher recognition context because it documents academic affiliation, biochemistry-related research activity, indexed publications, and measurable citation engagement. Final award suitability should be determined through the relevant evaluation process, including assessment of originality, research quality, contribution, publication evidence, and supporting documentation.

Conclusion

Hemantha Mani Kumar Chakravarthi Chanda represents an emerging scholarly profile in biochemistry, with four indexed documents, four citations, and an h-index of one. These indicators provide a concise view of current research activity, while continued publication, collaboration, and scientific development may provide additional evidence for future academic recognition.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Hemantha Mani Kumar Chakravarthi Chanda, Author ID 60154587000. Scopus.
    https://www.scopus.com/pages/authors/60154587000
  2. ORCID. (n.d.). ORCID record: Hemantha Mani Kumar Chakravarthi Chanda.
    https://orcid.org/0009-0008-3418-3374
  3. Best Paper Awards. (n.d.). Award information and recognition resources.
    https://bestpaperawards.com

Safa Tahmasebi | Biochemistry | Best Researcher Award | 10070

Dr. Safa Tahmasebi | Biochemistry | Best Researcher Award

PhD of Immunology at Shahid Beheshti University of Medical Sciences | Iran

Dr. Safa Tahmasebi is an accomplished researcher in medical immunology, with expertise in cancer immunotherapy, stem cell biology, exosome research, and immune regulation in infectious and autoimmune diseases. Holding a PhD in Medical Immunology from Shahid Beheshti University of Medical Sciences, she has led and collaborated on numerous impactful projects, including translational research on CAR-T and CAR-NK therapies and novel immunotherapeutic strategies. She has authored multiple publications in high-impact journals indexed in Scopus and PubMed, alongside contributions to books and international congresses where she has delivered invited lectures and top-ranked presentations. Beyond research, she has demonstrated leadership in student research committees, organized academic workshops, and contributed to community platforms. Her achievements reflect strong academic excellence, research innovation, and a commitment to advancing global healthcare through science and education.

Professional Profiles

Google Scholar | Scopus | Orcid

Education

Dr. Safa Tahmasebi has pursued a distinguished academic path in the field of medical sciences, consistently excelling at every stage. She completed her Bachelor’s degree in Laboratory Sciences, achieving first rank throughout her studies. She then earned a Master’s in Medical Immunology, securing top positions in the national entrance examinations, followed by a PhD in Medical Immunology from Shahid Beheshti University of Medical Sciences. During her doctoral studies, she specialized in advanced immunological mechanisms, cancer immunotherapy, and translational medicine, with a strong focus on CAR-T and CAR-NK therapies. Her educational background reflects academic excellence, perseverance, and a deep commitment to scientific advancement. The rigorous training she received has laid a strong foundation for her subsequent professional and research contributions, preparing her to lead innovative projects at both national and international levels.

Experience

Dr. Safa Tahmasebi has gained extensive professional experience as a researcher, educator, and academic leader. She has served as an executive and collaborator in multiple high-impact research projects, including studies on immunotherapy, stem cell applications, exosomes in cancer progression, and immune responses in infectious diseases. Her role extends beyond laboratory research into teaching, where she has conducted theoretical and practical courses in immunology for students in medicine, nursing, pharmacy, and dentistry. She has also organized advanced workshops on systematic reviews, SPSS, ELISA, and cancer immunology, equipping young researchers with essential scientific skills. Additionally, she has been actively involved in student research committees and community platforms, taking leadership roles in guiding scientific initiatives. Through these experiences, she has demonstrated a balance of research innovation, academic mentoring, and community engagement.

Research Interest

Dr. Safa Tahmasebi’s research interests lie at the intersection of immunology, oncology, and translational medicine, with a particular focus on innovative therapeutic strategies. Her primary work involves developing and improving cancer immunotherapies such as CAR-T and CAR-NK cell therapies, investigating tumor microenvironment dynamics, and exploring the roles of exosomes and non-coding RNAs in cancer progression. She is also deeply engaged in studying immune regulation in autoimmune and infectious diseases, including COVID-19, where she has published widely on vaccine responses and immunomodulatory therapies. Her interests extend to anti-aging research, stem cell-based therapies, and the application of artificial intelligence in cancer prediction and treatment. With an emphasis on bridging laboratory research with clinical application, her vision is to advance therapies that significantly improve patient outcomes and contribute to global health solutions.

Awards and Honors

Dr. Safa Tahmasebi has received numerous awards and honors that recognize her academic excellence, research achievements, and community contributions. She has consistently ranked first in national examinations for both her Master’s and PhD programs, highlighting her strong academic foundation. Her achievements include being selected as a model student at both institutional and provincial levels, receiving the National Student Dedication Award for social responsibility, and earning recognition from the National Elite Foundation through multiple Shahid Zazai Projects for top students. She has also been honored as the Outstanding Research Student and selected for the Immunology and Allergy Festival as a leading PhD researcher. These accolades reflect her commitment to scientific excellence, leadership, and service to society, reinforcing her reputation as a highly accomplished and respected young researcher.

Research Skills

Dr. Safa Tahmasebi possesses a comprehensive set of research skills that combine technical expertise with strong analytical and leadership abilities. She is proficient in advanced laboratory techniques such as cell culture, ELISA, flow cytometry, molecular biology methods, and immunological assays. Her expertise extends to systematic reviews, meta-analysis, and the application of statistical tools like SPSS for biomedical research. She has successfully led projects involving experimental models of cancer, immunomodulatory therapies, and exosome-based studies, demonstrating skill in both experimental design and translational application. Additionally, she has significant experience in academic writing, with numerous publications in high-impact journals, books, and conference proceedings. Her ability to lead interdisciplinary projects, collaborate internationally, and mentor students underscores her strengths not only as a researcher but also as an academic leader committed to advancing medical science.

Publication Top Notes

Title: CAR T cells in solid tumors: challenges and opportunities
Year: 2021
Citations: 660

Title: Exosome engineering in cell therapy and drug delivery
Year: 2023
Citations: 250

Title: Recent advances in non-small cell lung cancer targeted therapy; an update review
Year: 2023
Citations: 228

Title: Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Year: 2021
Citations: 202

Title: Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controls
Year: 2020
Citations: 184

Title: The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patients
Year: 2021
Citations: 171

Title: CAR-T cell combination therapy: the next revolution in cancer treatment
Year: 2022
Citations: 135

Title: Solid tumors challenges and new insights of CAR T cell engineering
Year: 2019
Citations: 122

Title: Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells
Year: 2018
Citations: 93

Title: CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Year: 2023
Citations: 74

Title: Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
Year: 2021
Citations: 74

Title: Chimeric antigen receptor-T cell therapy: Applications and challenges in treatment of allergy and asthma
Year: 2020
Citations: 73

Title: Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy
Year: 2020
Citations: 61

Title: The outlook for diagnostic purposes of the 2019‐novel coronavirus disease
Year: 2020
Citations: 49

Title: Study of immunomodulatory effects of mesenchymal stem cell-derived exosomes in a mouse model of LPS induced systemic inflammation
Year: 2022
Citations: 41

Title: Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in Cancer
Year: 2022
Citations: 40

Title: Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients
Year: 2020
Citations: 39

Title: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
Year: 2021
Citations: 38

Title: Mesenchymal stem cell-based therapy as a new therapeutic approach for acute inflammation
Year: 2023
Citations: 34

Title: Longevity and anti-aging effects of curcumin supplementation
Year: 2024
Citations: 33

Title: Recent advances in antibody‐based immunotherapy strategies for COVID‐19
Year: 2021
Citations: 33

Title: E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy
Year: 2021
Citations: 32

Title: IL-38 as an early predictor of the ischemic stroke prognosis
Year: 2021
Citations: 30

Title: Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2
Year: 2021
Citations: 30

Title: Immune-based therapy for COVID-19
Year: 2021
Citations: 26

Title: Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?
Year: 2024
Citations: 20

Title: Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function
Year: 2022
Citations: 16

Title: Epigenetic biomarkers in aging and longevity: Current and future application
Year: 2024
Citations: 15

Title: Cellular and biological factors involved in healing wounds and burns and treatment options in tissue engineering
Year: 2022
Citations: 15

Title: Handbook of cancer and immunology
Year: 2022
Citations: 15

Title: Artificial intelligence for prediction of metastasis risk and survival
Year: 2024
Citations: 11

Title: The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease
Year: 2023
Citations: 10

Title: CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies
Year: 2023
Citations: 9

Title: COVID-19: our current knowledge of epidemiology, pathology, therapeutic approaches, and diagnostic methods
Year: 2021
Citations: 9

Title: Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies
Year: 2025
Citations: 7

Title: Immunogenicity of COVID‐19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: a systematic review and meta‐analysis
Year: 2023
Citations: 7

Title: Recent innovative approaches to intensify the efficacy and safety of CAR-T cell therapy in cancers
Year: 2022
Citations: 6

Title: Glycolysis and Autoimmune Diseases: A Growing Relationship
Year: 2020
Citations: 6

Title: Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises
Year: 2025
Citations: 5

Title: Effect of genetic profiling on surgical decisions at hereditary colorectal cancer syndromes
Year: 2024
Citations: 5

Title: The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions
Year: 2021
Citations: 3

Title: Harnessing the fundamental roles of vitamins: the potent anti-oxidants in longevity
Year: 2025
Citations: 2

Title: Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies
Year: 2025
Citations: 2

Title: Harnessing IL-27: challenges and potential in cancer immunotherapy
Year: 2025
Citations: 2

Title: Anti-aging natural supplements: the main players in promoting healthy lifespan
Year: 2024
Citations: 2

Title: The Assessment of Anti–SARS‐CoV‐2 Antibodies in Different Vaccine Platforms
Year: 2024
Citations: 2

Title: Immunity to tetanus vaccination in pregnant women in Zanjan province, northwest of Iran
Year: 2018
Citations: 2

Title: Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progression
Year: 2025
Citation: 1

Title: CCAT2 role in gastrointestinal cancer progression and metastasis
Year: 2025
Citation: 1

Title: Breaking barriers: CAR-NK cell therapy breakthroughs in female-related cancers
Year: 2025
Citation: 1

Title: DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target
Year: 2025
Citation: 1

Title: Macrophage polarization in hepatocellular carcinoma: a lncRNA-centric perspective on tumor progression and metastasis
Year: 2025
Citation: 1

Title: Translating preclinical insights into clinical strategies: Targeting cancer stem cells and stemness in prostate cancer
Year: 2025
Citation: 1

Conclusion

In conclusion, Dr. Safa Tahmasebi represents an exceptional example of academic excellence, research innovation, and leadership in the field of medical immunology. With a strong educational foundation, extensive professional experience, and impactful research contributions in cancer immunotherapy, stem cell biology, and immune regulation, she has established herself as a promising scientist. Her awards and honors further demonstrate her commitment to excellence, while her diverse research skills highlight her ability to bridge theory and practice. Through her publications, lectures, and community involvement, she has already made significant contributions to science and society. With her vision for advancing immunological therapies and her ability to inspire and mentor others, she holds immense potential to continue making groundbreaking contributions and is highly deserving of recognition through prestigious research awards.